BR112021012133A8 - Forma 1 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, forma 4 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, e, composição farmacêutica - Google Patents

Forma 1 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, forma 4 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, e, composição farmacêutica

Info

Publication number
BR112021012133A8
BR112021012133A8 BR112021012133A BR112021012133A BR112021012133A8 BR 112021012133 A8 BR112021012133 A8 BR 112021012133A8 BR 112021012133 A BR112021012133 A BR 112021012133A BR 112021012133 A BR112021012133 A BR 112021012133A BR 112021012133 A8 BR112021012133 A8 BR 112021012133A8
Authority
BR
Brazil
Prior art keywords
deoxyadenosine
ethynyl
fluoro
anhydro form
crystalline
Prior art date
Application number
BR112021012133A
Other languages
English (en)
Other versions
BR112021012133A2 (pt
Inventor
Skomski Daniel
Su Yongchao
Xu Wei
Cubrovic Marko
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112021012133A2 publication Critical patent/BR112021012133A2/pt
Publication of BR112021012133A8 publication Critical patent/BR112021012133A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

FORMA 1 ANIDRA CRISTALINA DE 4’-ETINIL-2-FLUORO-2’- DESOXIADENOSINA, FORMA 4 ANIDRA CRISTALINA DE 4’-ETINIL- 2-FLUORO-2’-DESOXIADENOSINA, E, COMPOSIÇÃO FARMACÊUTICA. A presente descrição provê as novas formas cristalinas 1 e 4 de anidrato de 4-Etinil-2-fluoro-2-desoxiadenosina e composições farmacêuticas da mesma, cada uma da qual pode ser útil para a inibição de transcriptase reversa do HIV, o tratamento ou profilaxia de infecção pelo HIV e/ou o tratamento, profilaxia e/ou retardo do início ou progressão da AIDS ou ARC.
BR112021012133A 2018-12-20 2019-12-16 Forma 1 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, forma 4 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, e, composição farmacêutica BR112021012133A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782549P 2018-12-20 2018-12-20
US62/782,549 2018-12-20
PCT/US2019/066436 WO2020131649A1 (en) 2018-12-20 2019-12-16 Novel crystalline forms of an nrtti compound

Publications (2)

Publication Number Publication Date
BR112021012133A2 BR112021012133A2 (pt) 2021-09-08
BR112021012133A8 true BR112021012133A8 (pt) 2023-04-11

Family

ID=71100555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021012133A BR112021012133A8 (pt) 2018-12-20 2019-12-16 Forma 1 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, forma 4 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, e, composição farmacêutica

Country Status (10)

Country Link
US (1) US20220056067A1 (pt)
EP (1) EP3897660A4 (pt)
JP (1) JP7530899B2 (pt)
KR (1) KR20210105931A (pt)
CN (1) CN113194959A (pt)
AU (1) AU2019403024A1 (pt)
BR (1) BR112021012133A8 (pt)
CA (1) CA3122576A1 (pt)
MX (1) MX2021007544A (pt)
WO (1) WO2020131649A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3914604A4 (en) 2019-01-25 2022-10-19 Brown University COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING INFLAMMATION AND AGE-RELATED DISORDERS
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576752B1 (en) * 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EA201200144A1 (ru) * 2009-07-17 2012-08-30 Экселиксис, Инк. Кристаллические формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
GB0918431D0 (en) * 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
CA2813736C (en) * 2010-10-07 2020-03-24 Novartis Ag Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid
US10301281B2 (en) * 2014-12-11 2019-05-28 Merck Sharp & Dohme Corp. Crystal forms of a CCR5 antagonist
MX2018003212A (es) * 2015-09-23 2018-07-06 Merck Sharp & Dohme Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه

Also Published As

Publication number Publication date
KR20210105931A (ko) 2021-08-27
US20220056067A1 (en) 2022-02-24
CA3122576A1 (en) 2020-06-25
JP2022515718A (ja) 2022-02-22
AU2019403024A1 (en) 2021-07-15
CN113194959A (zh) 2021-07-30
EP3897660A1 (en) 2021-10-27
JP7530899B2 (ja) 2024-08-08
EP3897660A4 (en) 2022-09-07
WO2020131649A1 (en) 2020-06-25
MX2021007544A (es) 2021-08-11
BR112021012133A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
BR112021012133A8 (pt) Forma 1 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, forma 4 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, e, composição farmacêutica
EA201890425A1 (ru) Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения
MX2023002195A (es) Compuestos y metodos para el tratamiento de infecciones virales.
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
DOP2016000265A (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
MD3394033T2 (ro) Compuși heterociclici ca imunomodulatori
NI200900103A (es) Inhibidores de transcriptasa inversa no nucleosídicos
BR112015007742A2 (pt) composto, composição farmacêutica, método para a profilaxia ou tratamento da infecção pelo hiv ou para a profilaxia, tratamento, ou retardo do início da aids em um indivíduo, e, uso de um composto
TN2018000369A1 (fr) Aromatic sulfonamide derivatives.
NI201200146A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
NI201800083A (es) Procedimiento para el tratamiento y la profilaxis de vih y sida
MX2020010086A (es) Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.
BR112019002151A2 (pt) usos de compostos de fórmula (i) e usos de uma composição
DOP2006000176A (es) Inhibidores de la transcriptasa reversa de vih
AR107596A1 (es) Procedimientos para el tratamiento y la profilaxis de vih y sida
ECSP088126A (es) Inhibidores de la transcriptasa reversa de vih

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]